127 related articles for article (PubMed ID: 38273649)
21. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
22. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
23. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
[TBL] [Abstract][Full Text] [Related]
24.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
25. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel.
Chen CC; Raikow RB; Sonmez-Alpan E; Swerdlow SH
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):1-11. PubMed ID: 10937042
[TBL] [Abstract][Full Text] [Related]
26. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia.
Yikilmaz AŞ; Bakanay ŞM; Avcı DN; Akinci S; Falay M; Özet G; Dilek İ
Int J Hematol Oncol Stem Cell Res; 2023 Jan; 17(1):39-47. PubMed ID: 37638287
[No Abstract] [Full Text] [Related]
28. Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
Cavalcanti Júnior GB; Sales VS; Cavalcanti e Silva DG; Lopes MC; Paiva Ade S; da Fonseca HE; do Nascimento Júniors FF; Fernandes MZ
Acta Cir Bras; 2005; 20 Suppl 1():101-7. PubMed ID: 16186976
[TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.
Starostka D; Kriegova E; Kudelka M; Mikula P; Zehnalova S; Radvansky M; Papajik T; Kolacek D; Chasakova K; Talianova H
Cytometry B Clin Cytom; 2018 Jul; 94(4):576-587. PubMed ID: 29220870
[TBL] [Abstract][Full Text] [Related]
30. ROR1: an orphan becomes apparent.
Kipps TJ
Blood; 2022 Oct; 140(14):1583-1591. PubMed ID: 35580162
[TBL] [Abstract][Full Text] [Related]
31. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients.
Morice WG; Kurtin PJ; Hodnefield JM; Shanafelt TD; Hoyer JD; Remstein ED; Hanson CA
Mayo Clin Proc; 2008 Jul; 83(7):776-85. PubMed ID: 18613994
[TBL] [Abstract][Full Text] [Related]
33. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation.
Nelson BP; Variakojis D; Peterson LC
Mod Pathol; 2002 Nov; 15(11):1111-20. PubMed ID: 12429788
[TBL] [Abstract][Full Text] [Related]
34. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
35. CD5-negative, CD10-negative small B-cell leukemia: variant of chronic lymphocytic leukemia or a distinct entity?
Sheikh SS; Kallakury BV; Al-Kuraya KA; Meck J; Hartmann DP; Bagg A
Am J Hematol; 2002 Dec; 71(4):306-10. PubMed ID: 12447961
[TBL] [Abstract][Full Text] [Related]
36. Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias.
Shabani M; Asgarian Omran H; Farsangi MH; Vossough P; Sharifian RA; Toughe GR; Razavi SM; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Avicenna J Med Biotechnol; 2011 Jul; 3(3):119-25. PubMed ID: 23408747
[TBL] [Abstract][Full Text] [Related]
37. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of immunophenotype characteristics in 109 cases of B lineage chronic B lymphoid leukemia].
Wang AQ; Geng MJ; Zhu MQ; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1374-7. PubMed ID: 22169286
[TBL] [Abstract][Full Text] [Related]
39. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
[TBL] [Abstract][Full Text] [Related]
40. Post-translational modifications regulate signalling by Ror1.
Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
